<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963521</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000626786</org_study_id>
    <secondary_id>IPC-2006-011</secondary_id>
    <secondary_id>INCA-RECF-0628</secondary_id>
    <secondary_id>EUDRACT-2006-007093-29</secondary_id>
    <secondary_id>IPC-LADC</secondary_id>
    <nct_id>NCT00963521</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission</brief_title>
  <official_title>Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune&#xD;
      response to kill cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how&#xD;
      well it works in treating patients with acute myeloid leukemia in complete remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the tolerability of autologous dendritic cell vaccine in patients with acute&#xD;
           myelogenous leukemia in complete remission.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the emergence of an immune response.&#xD;
&#xD;
        -  Determine the relapse rate.&#xD;
&#xD;
        -  Assess the occurrence of residual disease.&#xD;
&#xD;
      OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by&#xD;
      autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events at 6 months</measure>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute myelogenous leukemia (AML)&#xD;
&#xD;
               -  Myelomonocytic (M4) or monocytic (M5) subtype&#xD;
&#xD;
               -  In second complete remission (CR) or later following CR1 lasting ≤ 12 months&#xD;
                  after chemotherapy that may have included an intensification regimen followed by&#xD;
                  autologous transplantation&#xD;
&#xD;
          -  No (15;17) translocation&#xD;
&#xD;
          -  No AML M3&#xD;
&#xD;
          -  HLA-A2 positivity&#xD;
&#xD;
          -  CD14 ≥ 20% on peripheral blood mononuclear cells&#xD;
&#xD;
          -  Circulating blasts ≥ 10 x 109/L (collected prior to chemotherapy) available&#xD;
&#xD;
          -  Must not be eligible for HLA-matched allogeneic transplantation&#xD;
&#xD;
          -  No progressive disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No contraindication to cytopheresis or chemotherapy&#xD;
&#xD;
          -  No HIV or HTLV positivity&#xD;
&#xD;
          -  No hepatitis B or C activation&#xD;
&#xD;
          -  No prior psychological disease&#xD;
&#xD;
          -  Not deprived of liberty and able to give consent&#xD;
&#xD;
          -  Must be able to speak and read French&#xD;
&#xD;
          -  No other cancer except for basal cell or cervical&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Chabannon, MD, PhD</last_name>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2009</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

